New Study Results on Blood Pressure Reduction to be Presented at SupplySide West

Patients with metabolic syndrome may benefit from a lifestyle management program that includes MegaNatural® BP grape seed extract

Approximately 40 percent of adults in the United States have metabolic syndrome. Considered a risk factor for both coronary artery disease and type 2 diabetes, metabolic syndrome is diagnosed when at least three of five conditions are present: abdominal obesity, insulin resistance (impaired glucose tolerance), low serum HDL, elevated serum triglycerides, and an elevated blood pressure.

A new study indicates that the use of MegaNatural BP grape seed extract in conjunction with lifestyle modification may effectively lower blood pressure in patients with metabolic syndrome. Results of the study will be presented by Dr. C. Tissa Kappagoda, M.B.B.S., Ph.D., F.A.C.C., during SupplySide West, which takes place October 18-20 in Las Vegas. Patients with metabolic syndrome are encouraged to increase their exercise levels, lose weight, eat more healthfully and stop smoking.

Recently, a placebo controlled trial was undertaken with 24 subjects with metabolic syndrome that documented the blood pressure lowering effect of MegaNatural BP grape seed extract. Two dosage levels (150 mg/day and 300 mg/day) and a placebo were given to three groups of eight patients respectively. After one month of treatment, there was a significant reduction in blood pressure in both groups given MegaNatural BP. There was no change in the group given the placebo. Also, subjects given 300 mg of MegaNatural BP had a significant decrease in the concentration of oxidized LDL in plasma.
"These new study results suggest that MegaNatural BP, with its strong anti-oxidant activity and favorable effects on blood pressure, could be of value in a lifestyle management program directed towards people who suffer from metabolic syndrome," says Dr. Kappagoda.

SupplySide West Presentation Details
Dr. C. Tissa Kappagoda's presentation will take place Thursday, October 19, 2006, from 1:00 p.m. to 1:50 p.m. in the Toscana rooms 3605 and 3609, third level The Venetian Hotel. Dr. Kappagoda is Professor of Medicine, Division of Cardiovascular Medicine, University of California, Davis and Director of Preventive Cardiology Program, University of California, Davis Medical Center, Sacramento

CONTACT: Sarah Clark
[email protected]

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.